PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application Depression - Market size and forecast 2018-2023 Anxiety and panic disorder - Market size and forecast 2018-2023 Other mental conditions - Market size and forecast 2018-2023 Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Market positioning of vendors Vendors covered Vendor classification Allergan Plc Eli Lilly and Co. GlaxoSmithKline Plc H. Lundbeck AS Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Application - Market share 2018-2023 (%) Exhibit 18: Comparison by application Exhibit 19: Depression - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Depression - Year-over-year growth 2019-2023 (%) Exhibit 21: Anxiety and panic disorder - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Prevalence of any anxiety disorder among US adults (2001-2003) Exhibit 23: Past year severity of any anxiety disorder among US adults (2001-2003) Exhibit 24: Anxiety and panic disorder - Year-over-year growth 2019-2023 (%) Exhibit 25: Other mental conditions - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Prevalence of OCD among US adults (2001-2003) Exhibit 27: Past year severity of OCD among US adults (2001-2003) Exhibit 28: Other mental conditions - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by application Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: North America - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in North America Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Europe Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 40: Asia - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in Asia Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 43: ROW - Year-over-year growth 2019-2023 (%) Exhibit 44: Top 3 countries in ROW Exhibit 45: Key leading countries Exhibit 46: Market opportunity Exhibit 47: Prevalence scenario of AMI in US in 2017 Exhibit 48: Prevalence scenario of SMI in US in 2017 Exhibit 49: SSRI exposure 91 days either side of LMP and prevalence of congenital abnormality (CA) in three countries Exhibit 50: Impact of drivers and challenges Exhibit 51: Geriatric population scenario in US in 2017 Exhibit 52: CDC statistics about mental disorder in geriatric population in US over past few decades Exhibit 53: Vendor landscape Exhibit 54: Landscape disruption Exhibit 55: Market positioning of vendors Exhibit 56: Vendors covered Exhibit 57: Vendor classification Exhibit 58: Allergan Plc - Vendor overview Exhibit 59: Allergan Plc - Business segments Exhibit 60: Allergan Plc - Organizational developments Exhibit 61: Allergan Plc - Geographic focus Exhibit 62: Allergan Plc - Segment focus Exhibit 63: Allergan Plc - Key offerings Exhibit 64: Allergan Plc - Key customers Exhibit 65: Eli Lilly and Co. - Vendor overview Exhibit 66: Eli Lilly and Co. - Business segments Exhibit 67: Eli Lilly and Co. - Organizational developments Exhibit 68: Eli Lilly and Co. - Geographic focus Exhibit 69: Eli Lilly and Co. - Segment focus Exhibit 70: Eli Lilly and Co. - Key offerings Exhibit 71: Eli Lilly and Co. - Key customers Exhibit 72: GlaxoSmithKline Plc - Vendor overview Exhibit 73: GlaxoSmithKline Plc - Business segments Exhibit 74: GlaxoSmithKline Plc - Organizational developments Exhibit 75: GlaxoSmithKline Plc - Geographic focus Exhibit 76: GlaxoSmithKline Plc - Segment focus Exhibit 77: GlaxoSmithKline Plc - Key offerings Exhibit 78: GlaxoSmithKline Plc - Key customers Exhibit 79: H. Lundbeck AS - Vendor overview Exhibit 80: H. Lundbeck AS - Business segments Exhibit 81: H. Lundbeck AS - Organizational developments Exhibit 82: H. Lundbeck AS - Geographic focus Exhibit 83: H. Lundbeck AS - Key offerings Exhibit 84: H. Lundbeck AS - Key customers Exhibit 85: Pfizer Inc. - Vendor overview Exhibit 86: Pfizer Inc. - Business segments Exhibit 87: Pfizer Inc. - Organizational developments Exhibit 88: Pfizer Inc. - Geographic focus Exhibit 89: Pfizer Inc. - Segment focus Exhibit 90: Pfizer Inc. - Key offerings Exhibit 91: Pfizer Inc. - Key customers Exhibit 92: Validation techniques employed for market sizing Exhibit 93: Definition of market positioning of vendors

Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, and Pfizer Inc.